Evidence map›Paper›PMID 40213993›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Caspase-6/Gasdermin C-Mediated Tumor Cell Pyroptosis Promotes Colorectal Cancer Progression Through CXCL2-Dependent Recruitment of Myeloid-Derived Suppressor Cells.

Hanchao Gao, Yikun Yao, Weilong Li, Zigan Xu, Wenjun Hu, Kewang Luo, Peishan Chen, Wanjing Shang, Shaodong Luan, Guojun Shi and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Involvement of the pyroptosis-HMGB1 axis in systemic diseases.Frontiers in cell and developmental biology · 2026
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. HMGB1: A Central Node in Cancer Therapy Resistance.International journal of molecular sciences · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hanchao GaoDepartment of Nephrology, Shenzhen Longhua District Central Hospital, Shenzhen Longhua District Key Laboratory for Diagnosis and Treatment of Chronic Kidney Disease, Shenzhen, Guangdong, 518110, China.
Yikun YaoShanghai Institute of Nutrition & Health, Chinese Academy of Science, Shanghai, 200031, China.
Weilong LiDepartment of Nephrology, Shenzhen Longhua District Central Hospital, Shenzhen Longhua District Key Laboratory for Diagnosis and Treatment of Chronic Kidney Disease, Shenzhen, Guangdong, 518110, China.
Zigan XuDepartment of Nephrology, Shenzhen Longhua District Central Hospital, Shenzhen Longhua District Key Laboratory for Diagnosis and Treatment of Chronic Kidney Disease, Shenzhen, Guangdong, 518110, China.
Wenjun HuDepartment of Anesthesiology, The 305 Hospital of Liberation Army of China (PLA), Beijing, 100036, China.
Kewang LuoDepartment of Medical Laboratory, People's Hospital of Longhua, Shenzhen, Guangdong, 518110, China.
Peishan ChenDepartment of Nephrology, Shenzhen Longhua District Central Hospital, Shenzhen Longhua District Key Laboratory for Diagnosis and Treatment of Chronic Kidney Disease, Shenzhen, Guangdong, 518110, China.
Wanjing ShangLymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Shaodong LuanDepartment of Nephrology, Shenzhen Longhua District Central Hospital, Shenzhen Longhua District Key Laboratory for Diagnosis and Treatment of Chronic Kidney Disease, Shenzhen, Guangdong, 518110, China.
Guojun ShiDepartment of Endocrinology and Metabolism, Medical Center for Comprehensive Weight Control, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.ORCID https://orcid.org/0000-0002-3098-6662
Mengtao CaoDepartment of Respiratory Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, 518110, China.
Pengfei ChenDepartment of Traumatic Orthopedics, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, 518110, China.ORCID https://orcid.org/0000-0001-9450-0185

Funding

Chinese Academy of Sciences 176GJHZ2023026MI;Division of Intramural Research of NIAID/NIHGuangdong Basic and Applied Basic Research Foundation 2025A1515012512;National Key R&D Program of China 2023YFC2306300;National Natural Science Foundation of China 92374118;Shenzhen Science and Technology Innovation Program JCYJ20220531092617039,JCYJ20240813153015020,JCYJ20240813153002004.
6 · The paper itself

Abstract

Gasdermin (GSDM) family proteins mediate inflammatory cell pyroptosis and exert critical contributions to the pathogenesis of gastrointestinal cancers, infections, and gut mucosal inflammation. Gasdermin C (GSDMC) is overexpressed in human colorectal cancer (CRC); however, the molecular mechanisms underlying GSDMC regulation of CRC tumorigenesis are largely elusive. Here, it is found that both GSDMC expression and activation are significantly elevated in human and mouse CRC tissues. Gsdmc2/3/4 deficiency attenuates tumor progression in both chemically induced CRC mouse model and spontaneous intestinal tumor model. Mechanistically, under hypoxia and low-glucose condition, GSDMC2/3/4 are directly activated by Caspase-6, but not by Caspase-8, as previously reported in other cancers. GSDMC2/3/4-mediated pyroptosis in tumor cells leads to the release of high mobility group protein B1 (HMGB1), which enhances the expression of chemokine attractant C-X-C motif chemokine 2 (CXCL2) in surrounding tumor cells. Subsequently, the elevated CXCL2 secretion from tumor cells promotes the recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment (TME) through C-X-C chemokine receptor type 2 (CXCR2), thereby facilitating CRC progression. These findings reveal a mechanism by which Caspase-6/GSDMC-mediated tumor cell pyroptosis, in response to hypoxic and low-glucose conditions, remodels the immunosuppressive microenvironment through CXCL2-dependent recruitment of MDSCs. These results identify GSDMC as a potential drug target for CRC therapy.

Indexed as

Chemokine CXCL2Colorectal NeoplasmsMyeloid-Derived Suppressor CellsPhosphate-Binding ProteinsPyroptosisAnimalsCell Line, TumorDisease Models, AnimalDisease ProgressionGasderminsHumansMiceMice, Inbred C57BLChemokine CXCL2GasderminsGsdmd protein, mousePhosphate-Binding Proteinscolorectal cancerCXCL2GSDMCHMGB1myeloid‐derived suppressor cells

Identifiers

PMID40213993
PMCPMC12120772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.